Portal Hypertension in a Patient with Recurrent Pancreatic Cancer after Radiotherapy and Systemic Chemotherapy
Xingshun Qi,Ji Feng,Xiaodong Shao,Ying Xu,Hongyu Li,Xiaozhong Guo
DOI: https://doi.org/10.1016/j.jceh.2017.11.005
2017-01-01
Journal of Clinical and Experimental Hepatology
Abstract:Portal hypertension secondary to pancreatic cancer is rare in everyday clinical practice.1Tzeng Y.D. Liu S.I. Tsai C.C. An unusual cause of haematemesis: left-sided portal hypertension due to a large pancreatic tumour.Dig Liver Dis. 2012; 44: e12Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar The potential mechanism of disease should be portal and splenic vein involvement from pancreatic cancer. This abnormality is also termed as sinistral or left-sided portal hypertension presenting with isolated gastric varices, splenomegaly, and normal liver function. Notably, portal hypertension related complications are often the initial clinical presentations at the diagnosis of pancreatic cancer.2Li X.B. Zhao L. Liao Q. et al.Gastroesophageal varices (bleeding) and splenomegaly: the initial manifestations of some pancreatic body and tail carcinoma.Chin Med J (Engl). 2015; 128: 558-561Crossref PubMed Scopus (4) Google Scholar However, to the best of our knowledge, few studies reported the dynamic evolution of portal hypertension after non-surgical treatment of pancreatic cancer. Herein, we reported a case with recurrent pancreatic cancer after successful radiotherapy and systemic chemotherapy for 4 years who developed upper gastrointestinal bleeding from portal hypertension. A 57-year-old male presented with intermittent hematemesis and melena for 3 days at our department. He had a 4-year history of pancreatic cancer treated with radiotherapy and systemic chemotherapy. He denied any history of viral hepatitis and alcohol and drug abuse. At the admission, laboratory tests demonstrated that hemoglobin concentration was 49 g/L (130–175 g/L), hemocrit was 13.9% (40–50%), platelets was 387 × 109/L (125–350 × 109/L), white blood cell was 18.5 × 109/L (3.5–9.5 × 109/L), total bilirubin was 9.0 μmol/L (5.1–22.2 μmol/L), alanine aminotransferase was 30.69 U/L (9–50 U/L), aspartate aminotransferase was 38.47 U/L (15–40 U/L), alkaline phosphatase was 119.73 U/L (45–125 U/L), gamma glutamyl transpeptidase was 91.39 U/L (10–60 U/L), albumin was 26.9 g/L (40–55 g/L), prothrombin time was 16.8 s (11.5–14.5 s), and international normalized ratio was 1.34. Blood transfusion was given. After that, an emergent upper gastrointestinal endoscopy demonstrated esophageal and duodenal varices, portal hypertensive gastrophy, multiple shallow duodenal ulcers, and a duodenal mass. He received intravenous infusion of terlipressin and esomeprazole and underwent endoscopic esophageal variceal ligation. Contrast-enhanced computed tomography scans were performed. Meanwhile, we compared the findings from contrast-enhanced computed tomography and magnetic resonance scans performed earlier at our hospital. Main portal trunk and superior mesenteric vein became thinner, splenic vein disappeared, spleen enlarged, and moderate ascites occurred (Figure 1). Thus, he was diagnosed with portal hypertension secondary to pancreatic cancer. At the discharge, laboratory tests demonstrated that hemoglobin concentration was 90 g/L, hemocrit was 28.8%, platelets was 159 × 109/L, white blood cell was 5.7 × 109/L, total bilirubin was 12.6 μmol/L, alanine aminotransferase was 13.15 U/L, aspartate aminotransferase was 23.96 U/L, alkaline phosphatase was 108.95 U/L, gamma glutamyl transpeptidase was 68.57 U/L, albumin was 30.8 g/L, prothrombin time was 16.0 s, and international normalized ratio was 1.26. Now, he is receiving oral propranolol without recurrence of gastrointestinal bleeding. This case report clearly showed a deterioration of portal vein system vessels in recurrent pancreatic cancer after radiotherapy and systemic chemotherapy, such as narrowing of portal and superior mesenteric veins and fibrosing of splenic vein, which eventually led to the occurrence of extrahepatic portal hypertension. Pharmacological and endoscopic treatments are given according to the current practice guideline regarding the management of varices and variceal bleeding in liver cirrhosis.3Garcia-Tsao G. Abraldes J.G. Berzigotti A. Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.Hepatology. 2017; 65: 310-335Crossref PubMed Scopus (1074) Google Scholar Certainly, the outcome of this patient may be mainly dependent upon the management of pancreatic cancer, except for variceal bleeding. The authors have none to declare.